MANTICORE 101-Breast
2017
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research 101-Breast
In 94 patients with HER2-positive early breast cancer starting adjuvant trastuzumab, perindopril or bisoprolol did not prevent trastuzumab-mediated left ventricular remodelling, although both attenuated the fall in ejection fraction, compared with placebo.
Result
Primary endpoint: Change in indexed left ventricular end-diastolic volume on cardiac MRI
Indexed end-diastolic volume +7 (perindopril), +8 (bisoprolol) and +4 mL/m² (placebo; p=0.36): primary endpoint neutral. LVEF decline attenuated with bisoprolol −1%, vs perindopril −3% and placebo −5% (p=0.001).
- Subtopic
- HER2 cardiotoxicity
- Design
- Double-blind, placebo-controlled RCT with three parallel arms
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2022 Cardio-Oncology
- Source
- Pituskin E, Mackey JR, Koshman S, et al. J Clin Oncol. 2017;35(8):870-877.doi 10.1200/JCO.2016.68.7830
Discussion & critique
The primary remodelling endpoint was formally negative, so the positive ejection-fraction finding is secondary and hypothesis-generating. It is still the best randomised evidence for neurohormonal prophylaxis specifically under anti-HER2 therapy.